Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer

Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer

Estrogen receptor alpha (ER) is the oncogenic driver for ER+ breast cancer (BC). ER antagonists are the standard-of-care treatment for ER+ BC; however, primary and acquired resistance to these agents is common. CBP and p300 are critical ER co-activators and their acetyltransferase (KAT) domain and a...

Full description

Bibliographic Details
Main Authors: Aaron Waddell, Iqbal Mahmud, Haocheng Ding, Zhiguang Huo, Daiqing Liao
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
breast cancer
estrogen receptor
CBP/p300 acetyltransferases
histone acetylation
bromodomain
enhancers
Online Access:https://www.mdpi.com/2072-6694/13/11/2799

Internet

https://www.mdpi.com/2072-6694/13/11/2799

Similar Items